Literature DB >> 22154935

Chop (Ddit3) is essential for D469del-COMP retention and cell death in chondrocytes in an inducible transgenic mouse model of pseudoachondroplasia.

Karen L Posey1, Francoise Coustry, Alka C Veerisetty, Peiman Liu, Joseph L Alcorn, Jacqueline T Hecht.   

Abstract

Cartilage oligomeric matrix protein (COMP), a secreted glycoprotein synthesized by chondrocytes, regulates proliferation and type II collagen assembly. Mutations in the COMP gene cause pseudoachondroplasia and multiple epiphyseal dysplasia. Previously, we have shown that expression of D469del-COMP in transgenic mice causes intracellular retention of D469del-COMP, thereby recapitulating pseudoachondroplasia chondrocyte pathology. This inducible transgenic D469del-COMP mouse is the only in vivo model to replicate the critical cellular and clinical features of pseudoachondroplasia. Here, we report developmental studies of D469del-COMP-induced chondrocyte pathology from the prenatal period to adolescence. D469del-COMP retention was limited prenatally and did not negatively affect the growth plate until 3 weeks after birth. Results of immunostaining, transcriptome analysis, and qRT-PCR suggest a molecular model in which D469del-COMP triggers apoptosis during the first postnatal week. By 3 weeks (when most chondrocytes are retaining D469del-COMP), inflammation, oxidative stress, and DNA damage contribute to chondrocyte cell death by necroptosis. Importantly, by crossing the D469del-COMP mouse onto a Chop null background (Ddit3 null), thereby eliminating Chop, the unfolded protein response was disrupted, thus alleviating both D469del-COMP intracellular retention and premature chondrocyte cell death. Chop therefore plays a significant role in processes that mediate D469del-COMP retention. Taken together, these results suggest that there may be an optimal window before the induction of significant D469del-COMP retention during which endoplasmic reticulum stress could be targeted.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22154935      PMCID: PMC3349877          DOI: 10.1016/j.ajpath.2011.10.035

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  58 in total

1.  Pseudoachondroplastic dwarfism. A rough-surfaced endoplasmic reticulum storage disorder.

Authors:  R R Cooper; I V Ponseti; J A Maynard
Journal:  J Bone Joint Surg Am       Date:  1973-04       Impact factor: 5.284

2.  Swelling pressures of proteoglycans at the concentrations found in cartilaginous tissues.

Authors:  J P Urban; A Maroudas; M T Bayliss; J Dillon
Journal:  Biorheology       Date:  1979       Impact factor: 1.875

3.  Cartilage matrix proteins. An acidic oligomeric protein (COMP) detected only in cartilage.

Authors:  E Hedbom; P Antonsson; A Hjerpe; D Aeschlimann; M Paulsson; E Rosa-Pimentel; Y Sommarin; M Wendel; A Oldberg; D Heinegård
Journal:  J Biol Chem       Date:  1992-03-25       Impact factor: 5.157

4.  Interactions between the cartilage oligomeric matrix protein and matrilins. Implications for matrix assembly and the pathogenesis of chondrodysplasias.

Authors:  Henning H Mann; Suat Ozbek; Jürgen Engel; Mats Paulsson; Raimund Wagener
Journal:  J Biol Chem       Date:  2004-04-09       Impact factor: 5.157

5.  Cartilage oligomeric matrix protein and thrombospondin 1. Purification from articular cartilage, electron microscopic structure, and chondrocyte binding.

Authors:  P E DiCesare; M Mörgelin; K Mann; M Paulsson
Journal:  Eur J Biochem       Date:  1994-08-01

6.  Chondrocyte cell death and intracellular distribution of COMP and type IX collagen in the pseudoachondroplasia growth plate.

Authors:  Jacqueline T Hecht; Outi Makitie; Elizabeth Hayes; Richard Haynes; Miki Susic; Dina Montufar-Solis; P Jackie Duke; William G Cole
Journal:  J Orthop Res       Date:  2004-07       Impact factor: 3.494

7.  Effects of proteoglycan extraction on the tensile behavior of articular cartilage.

Authors:  M B Schmidt; V C Mow; L E Chun; D R Eyre
Journal:  J Orthop Res       Date:  1990-05       Impact factor: 3.494

8.  Cartilage oligomeric matrix protein: isolation and characterization from human articular cartilage.

Authors:  P E DiCesare; M Mörgelin; C S Carlson; S Pasumarti; M Paulsson
Journal:  J Orthop Res       Date:  1995-05       Impact factor: 3.494

9.  Pseudoachondroplasia and multiple epiphyseal dysplasia due to mutations in the cartilage oligomeric matrix protein gene.

Authors:  M D Briggs; S M Hoffman; L M King; A S Olsen; H Mohrenweiser; J G Leroy; G R Mortier; D L Rimoin; R S Lachman; E S Gaines
Journal:  Nat Genet       Date:  1995-07       Impact factor: 38.330

10.  Mutations in exon 17B of cartilage oligomeric matrix protein (COMP) cause pseudoachondroplasia.

Authors:  J T Hecht; L D Nelson; E Crowder; Y Wang; F F Elder; W R Harrison; C A Francomano; C K Prange; G G Lennon; M Deere
Journal:  Nat Genet       Date:  1995-07       Impact factor: 38.330

View more
  19 in total

1.  Mutant cartilage oligomeric matrix protein (COMP) compromises bone integrity, joint function and the balance between adipogenesis and osteogenesis.

Authors:  Francoise Coustry; Karen L Posey; Tristan Maerz; Kevin Baker; Annie M Abraham; Catherine G Ambrose; Sabah Nobakhti; Sandra J Shefelbine; Xiaohong Bi; Michael Newton; Karissa Gawronski; Lindsay Remer; Alka C Veerisetty; Mohammad G Hossain; Frankie Chiu; Jacqueline T Hecht
Journal:  Matrix Biol       Date:  2018-01-05       Impact factor: 11.583

Review 2.  Novel therapeutic interventions for pseudoachondroplasia.

Authors:  Karen L Posey; Jacqueline T Hecht
Journal:  Bone       Date:  2017-03-21       Impact factor: 4.398

Review 3.  Extracellular matrix and developing growth plate.

Authors:  Johanna Myllyharju
Journal:  Curr Osteoporos Rep       Date:  2014-12       Impact factor: 5.096

4.  Novel mTORC1 Mechanism Suggests Therapeutic Targets for COMPopathies.

Authors:  Karen L Posey; Francoise Coustry; Alka C Veerisetty; Mohammad G Hossain; Michael J Gambello; Jacqueline T Hecht
Journal:  Am J Pathol       Date:  2019-01       Impact factor: 4.307

5.  Inhibiting the integrated stress response pathway prevents aberrant chondrocyte differentiation thereby alleviating chondrodysplasia.

Authors:  Cheng Wang; Zhijia Tan; Ben Niu; Kwok Yeung Tsang; Andrew Tai; Wilson C W Chan; Rebecca L K Lo; Keith K H Leung; Nelson W F Dung; Nobuyuki Itoh; Michael Q Zhang; Danny Chan; Kathryn Song Eng Cheah
Journal:  Elife       Date:  2018-07-19       Impact factor: 8.140

6.  Antisense Reduction of Mutant COMP Reduces Growth Plate Chondrocyte Pathology.

Authors:  Karen L Posey; Francoise Coustry; Alka C Veerisetty; Mohammad Hossain; Danielle Gattis; Sheri Booten; Joseph L Alcorn; Punit P Seth; Jacqueline T Hecht
Journal:  Mol Ther       Date:  2017-02-03       Impact factor: 11.454

7.  Clinical, Biochemical, Radiological, Genetic and Therapeutic Analysis of Patients with COMP Gene Variants.

Authors:  Hanting Liang; Yanfang Hou; Qianqian Pang; Yan Jiang; Ou Wang; Mei Li; Xiaoping Xing; Huijuan Zhu; Weibo Xia
Journal:  Calcif Tissue Int       Date:  2021-10-28       Impact factor: 4.333

8.  Joint Degeneration in a Mouse Model of Pseudoachondroplasia: ER Stress, Inflammation, and Block of Autophagy.

Authors:  Jacqueline T Hecht; Alka C Veerisetty; Mohammad G Hossain; Debabrata Patra; Frankie Chiu; Francoise Coustry; Karen L Posey
Journal:  Int J Mol Sci       Date:  2021-08-26       Impact factor: 6.208

9.  Chondrocyte-specific pathology during skeletal growth and therapeutics in a murine model of pseudoachondroplasia.

Authors:  Karen L Posey; Francoise Coustry; Alka C Veerisetty; Peiman Liu; Joseph L Alcorn; Jacqueline T Hecht
Journal:  J Bone Miner Res       Date:  2014       Impact factor: 6.741

10.  Antioxidant and anti-inflammatory agents mitigate pathology in a mouse model of pseudoachondroplasia.

Authors:  Karen L Posey; Francoise Coustry; Alka C Veerisetty; Mohammad Hossain; Joseph L Alcorn; Jacqueline T Hecht
Journal:  Hum Mol Genet       Date:  2015-04-09       Impact factor: 5.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.